Global Antifungal Drugs Market 2018-2022
|発行||TechNavio (Infiniti Research Ltd.)||商品コード||475046|
|出版日||ページ情報||英文 97 Pages
Use of antifungal infections is expected to drive growth in the market. Research has shown synergism between many antifungals, which has led to an increase in clinicians prescribing combination therapies over monotherapies. Also, availability of antifungals with novel mechanisms of actions has promoted the trend of using combinations. Technavio's analysts have predicted that the antifungal drugs market will register a CAGR of over 3% by 2022.
An increase in funding for antifungal research is another key factor contributing to the growth of the global antifungal drugs market. In many European countries, government funding is also available for research in fungal diseases.
Antifungals are often associated with mild adverse effects like itching, redness, abdominal pain, and diarrhea.
For the detailed list of factors that will drive and challenge the growth of the antifungal drugs market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the use of antifungal infections and the increase in antifungal research funding, will provide considerable growth opportunities to antifungal drugs manufactures. Astellas Pharma, Basilea Pharmaceutica, Merck, and Pfizer are some of the major companies covered in this report.